Maryland 2024 Regular Session

Maryland House Bill HB1421

Introduced
2/9/24  

Caption

Food, Drugs, and Cosmetics - Gene Structure- and Function-Modifying Products - Labeling

Impact

If enacted, HB1421 will significantly alter the legal framework surrounding food, drugs, and cosmetics by establishing clear guidelines that these gene-altering products must meet before being marketed to consumers. Mandatory labeling will provide information on all potential risks, side effects, and adverse effects to consumers, thereby enhancing transparency and aiding informed decision-making. This bill seeks to protect public health by ensuring that consumers are not left unaware of the implications of modifying products they may purchase that could affect their health or well-being.

Summary

House Bill 1421 introduces new regulatory measures regarding gene structure and function-modifying products in the state. This legislation is intended to ensure that all products which utilize modern biotechnology methods—including gene editing, RNA interference, and transgenesis—are clearly labeled before being sold. The bill defines gene structure-modifying products and sets stringent labeling requirements to inform consumers of potential risks and side effects associated with these modern biotechnology products. The regulations aim to bolster consumer awareness and safety in the marketplace.

Contention

While proponents of the bill argue for an imperative need for enhanced labeling to protect consumer health, there are concerns among certain stakeholders about how these regulations could influence market dynamics and inhibit innovation in biotechnological advancements. Critics may contend that overly restrictive regulations could increase costs for producers and potentially limit the competitiveness of the state's biotech sector. Further discussions are likely to raise questions about the balance between consumer safety and the economic implications for businesses involved in biotechnology.

Companion Bills

MD SB911

Crossfiled Food, Drugs, and Cosmetics - Gene Structure- and Function-Modifying Products - Labeling

Previously Filed As

MD SB124

Food, Drugs, and Cosmetics - Gene Structure- and Function-Modifying Products - Labeling

MD HB398

Food, drugs, and cosmetics; authorize production and sale of cottage food items with certain exemptions, requirements, and disclosures

MD A11360

Requires the labeling of certain baby cosmetic products

MD HB8

Public Health - Food and Milk Product Labeling - Requirements

MD SB546

Public Health - Food and Milk Product Labeling - Requirements

MD HB2762

food products; labeling; cultivated cells

MD HB913

Meat labeling; require accurate labeling of meat and nonmeat products by processors, retail and food establishment prior to final sale.

MD HB1305

Meat labeling; require accurate labeling of meat and nonmeat products by processors, retail and food establishments prior to final sale.

MD SB1577

Relating to the labeling of alternative protein food products.

MD H3096

Gene Therapy

Similar Bills

MD SB124

Food, Drugs, and Cosmetics - Gene Structure- and Function-Modifying Products - Labeling

MA S2967

Providing for the ownership and maintenance of the Town Line Brook and Linden Brook culverts and dams

NY A11342

Enacts the "Give Kids a Chance - Carter and Ray's Law"; mandates health insurance coverage for congenital anomalies

MA S620

Providing for the ownership and maintenance of the Town Line Brook and Linden Brook culverts and dams

MA H956

Providing for the ownership and maintenance of the Town Line Brook and Linden Brook culverts and dams

TX HB3004

Relating to work, an activity, or a function performed near a high voltage overhead line.

NY S09649

Enacts the "Give Kids a Chance - Carter and Ray's Law" mandating health insurance coverage for congenital anomalies including certain reconstructive services, habilitative services, and inpatient and outpatient services.

MS SB2671

Podiatric medicine and podiatrists; revise definitions and provisions related thereto.